One prospective study was underpowered to assess for differences in cardiac dysfunction between groups, excluded participants with hypertension or those who received trastuzumab, and did not demonstrate expected LVEF declines among BRCA1/2 mutation carriers receiving anthracyclines (4). Here, BRCA1 is linked to Hypertension.